Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplantin vivoT‐cell depletion with anti‐thymocyte globulin
Open Access
- 1 June 2001
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 113 (4) , 1060-1071
- https://doi.org/10.1046/j.1365-2141.2001.02849.x
Abstract
We evaluated the cytomegalovirus (CMV) serostatus as a risk factor for survival and treatment‐related mortality (TRM) in 125 patients allografted from an unrelated donor between 1994 and 1999. All patients received pretransplantin vivoT‐cell depletion using rabbit anti‐thymocyte globulin (ATG). Only one patient had primary graft failure and severe grade III/IV graft‐versus‐host disease occurred in 14% of the patients. The overall survival (OS) at 3 years was 70% for CMV‐negative patients (n = 76) and 29% in the seropositive cohort (n = 49) (P > 0·001). In multivariate analyses, CMV seropositivity remained an independent negative prognostic factor for OS (RR: 2·1; CI: 1·2–3·8;P = 0·014), apart from age > 20 years (RR: 2·74; CI: 1·2–3·8;P = 0·004) and late leucocyte engraftment (RR: 2·4; CI: 1·2–4·9;P = 0·015). The TRM for all patients was 27%. Despite monitoring for CMV antigenaemia and preemptive therapy with ganciclovir when reactivation occurred, seropositive patients had a three times higher risk of fatal treatment‐related complications than seronegative patients. In multivariate analyses, CMV seropositivity remained the strongest independent negative factor for TRM (RR: 5·3; CI: 1·9–14·6;P = 0·002), followed by age > 20 years (RR: 4·8; CI: 1·3–18·1;P = 0·02) and delayed leucocyte engraftment (RR: 3·6; CI: 1·2–11;P = 0·02). The TRM was identical in seropositive patients with (n = 27) or without (n = 22) CMV reactivation (44% versus 50%). We conclude that CMV seropositivity, despite preemptive ganciclovir therapy and even without reactivation, is a major negative prognostic factor for survival as well as for TRM in unrelated stem cell transplantation using pretransplantin vivoT‐cell depletion with ATG.Keywords
This publication has 43 references indexed in Scilit:
- Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCTBone Marrow Transplantation, 2000
- The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemiaBone Marrow Transplantation, 2000
- Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrowBone Marrow Transplantation, 1999
- Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid LeukemiaNew England Journal of Medicine, 1998
- Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantationClinical and Experimental Immunology, 1992
- Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphomaHuman Immunology, 1990
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958